Lee Y-C, Wu C-T, Shih J-Y, Jou Y-S, Chang Y-L
Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100, Taiwan.
Br J Cancer. 2004 Jun 14;90(12):2378-83. doi: 10.1038/sj.bjc.6601778.
The fragile histidine triad (FHIT) gene, encompassing the FRA3B fragile site at chromosome 3p14.2, is a tumour suppressor gene involved in different tumour types including non-small-cell lung cancers (NSCLCs). In the current study, we examined for allelic deletion at the FHIT locus in 58 primary and microdissected NSCLCs, for which a clinicopathologic profile was available. We found a loss of 87.7% in heterozygosity (LOH) frequency at one or more microsatellite markers (D3S1289, D3S2408, D3S1766, D3S1312, D3S1600). Allelic deletion of D3S1766 was related to tumour histology in 10 of 11 squamous cell carcinomas (90.9%) displaying LOH compared with nine of 17 adenocarcinomas (52.9%; P=0.049). Besides, in the subset of adenocarcinomas, a higher rate of LOH at D3S1289 was observed in male (six out of eight, 75%) than in female patients (four out of 17, 23.5%; P=0.028). However, FHIT LOH was not correlated overall with a variety of clinical parameters including sex, smoking status, staging, lymph node metastasis and survival. These results indicated that the high frequency of FHIT gene disruption was important in the development of both squamous cell carcinomas and adenocarcinomas. Furthermore, there was no association between LOH at FHIT and protein expression, suggesting the presence of complex mechanisms of Fhit inactivation. On the other hand, the association between FHIT LOH and p53 protein overexpression assessment reached statistical significance (P=0.026), implying that common alterations affect the two genes in tumour progression.
脆性组氨酸三联体(FHIT)基因包含位于染色体3p14.2的FRA3B脆性位点,是一种肿瘤抑制基因,参与包括非小细胞肺癌(NSCLC)在内的不同肿瘤类型的发生发展。在本研究中,我们检测了58例原发性及显微切割的NSCLC中FHIT基因座的等位基因缺失情况,这些病例均有临床病理资料。我们发现,在一个或多个微卫星标记(D3S1289、D3S2408、D3S1766、D3S1312、D3S1600)处,杂合性缺失(LOH)频率为87.7%。在11例显示LOH的鳞状细胞癌中有10例(90.9%)D3S1766的等位基因缺失,而在17例腺癌中有9例(52.9%)出现该情况,二者相比差异有统计学意义(P=0.049)。此外,在腺癌亚组中,男性患者(8例中有6例,75%)D3S1289处的LOH发生率高于女性患者(17例中有4例,23.5%;P=0.028)。然而,总体而言,FHIT基因的LOH与包括性别、吸烟状况、分期、淋巴结转移及生存等多种临床参数均无相关性。这些结果表明,FHIT基因破坏的高频率在鳞状细胞癌和腺癌的发生发展中均具有重要意义。此外,FHIT基因的LOH与蛋白表达之间无关联,提示Fhit失活存在复杂机制。另一方面,FHIT基因的LOH与p53蛋白过表达评估之间的关联具有统计学意义(P=0.026),这意味着在肿瘤进展过程中,常见的改变会影响这两个基因。